1)Lunney JR, et al:Patterns of functional decline at the end of life. JAMA 289:2387-2392, 2003
2)Delima M, et al:Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 93:89-95, 1996
3)Itzykson R, et al:Azacytidine(AZA)in MDS(including RAEB-t and CMML)in Patients(pts)≥80 Years;Results of the French ATU Program. Blood 114:1773, 2009
4)Druker BJ, et al:Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
5)Kantarjian H, et al:Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002